Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: press clippings (3)

CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel
heltzeninvestorpress clippings
Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)December 15, 2025
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of Energy
nutraceuticalsmedicinepress clippingsperrimanNCT
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of EnergyNovember 26, 2025
Fast Company: eXoZymes permite producir compuestos antes imposibles de fabricar gracias a la IA
press clippings
Fast Company: eXoZymes permite producir compuestos antes imposibles de fabricar gracias a la IANovember 21, 2025
LA Weekly: The Enzyme Frontier: eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma
investornutraceuticalsmedicinepress clippingscannabinoids
LA Weekly: The Enzyme Frontier - eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and PharmaNovember 20, 2025
Slack Capital report
investorpress clippings
Slack Capital report: EXOZ is a once-in-a-lifetime opportunityNovember 19, 2025
'The Upside' interview: Michael Heltzen & Lou Basenese
heltzeninvestornutraceuticalsmedicinepress clippingsvideoNCTcannabinoids
'The Upside' interview: Michael Heltzen & Lou BaseneseNovember 18, 2025
CEO, Michael Heltzen is interviewed by Jane King
heltzeninvestorpress clippingsvideo
Jane King interviews CEO, Michael Heltzen, in New YorkNovember 12, 2025
Lightning Rx, Colette Nataf
press clippingspodcast
Podcast: Lightning Rx' Colette Nataf interviews CEO Heltzen on future of biomanufacturingOctober 22, 2025
Podcast: 'The Catalyst' interviews CEO, Michael Heltzen
heltzenpress clippingsvideopodcast
Podcast: 'The Catalyst' interviews CEO, Michael HeltzenOctober 17, 2025
Zachary Karl, Vice President Business Development @ Bio Innovations Midwest 2025
press clippingsvideo
World Bio Markets: AI - A tool U.S. industrial biomanufacturing cannot ignoreOctober 8, 2025
Previous page
Page 3 of 5
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark